
Cervical cancer treatment in Germany is planned around the stage, which changes everything here: small tumours are usually operated on, sometimes preserving fertility, while locally advanced disease is treated with chemoradiation.
Patients come to Germany for an exact stage before treatment and for a tumour board, not one doctor, to choose between surgery and radiotherapy. Nothing is decided before the slides and images have been reviewed. At LMU University Hospital in Munich, for example, the gynaecological cancer centre is led by Prof. Sven Mahner, and gynaecologists, radiologists, pathologists and radiation oncologists plan treatment together.
What is confirmed before treatment starts
Before treatment, the diagnosis and stage are confirmed again: the local pathologist reviews the existing slides and blocks. If needed, liquid-based cytology and PCR testing for high-risk human papillomavirus are repeated, and a tumour that cannot be assessed clearly is examined by extended colposcopy with targeted biopsy.
Beyond the earliest stage, German guidelines make a high-resolution pelvic MRI standard before surgery or radiotherapy is planned: it shows how far the tumour has grown and whether lymph nodes look affected. Only a few patients need PET-CT, mostly at recurrence, when distant metastases are suspected and other scans are unclear. This all comes first, because the stage decides whether surgery makes sense.
Surgery: when the uterus can be preserved
In cervical cancer treatment in Germany, the uterus can be preserved when the tumour is small, the lymph nodes are clear and the woman wants children: once the tumour board has confirmed that surgery is possible, she may be offered radical trachelectomy, the fertility-sparing option. It removes the cervix, upper vagina and parametrium (the surrounding tissue) but keeps the body of the uterus and the ovaries. Pregnancy is then possible under close supervision, though miscarriage and premature birth are more likely.
If the uterus need not or cannot be kept, early-stage disease is treated by radical hysterectomy using the Wertheim method, which removes the uterus with its ligaments and surrounding tissue, the upper vagina and the pelvic lymph nodes. The ovaries are removed after the menopause and can be kept before it. More advanced tumours usually receive chemoradiation instead.
In Germany radical hysterectomy is usually performed as open surgery. Laparoscopy and the Da Vinci robot-assisted system have not become standard: a large international trial found more recurrences after keyhole surgery, so German guidelines prefer the open approach. The approach follows the stage, not a wish; a gynaecological oncologist such as Prof. Martin Pölcher, who specialises in minimally invasive surgery, chooses the extent and technique. More on surgery for cervical cancer.
Chemoradiation and brachytherapy
Chemoradiation becomes the main treatment, not an add-on, when the tumour has grown into surrounding tissue or reached the lymph nodes; after surgery it is added if the risk of recurrence stays high. External beam radiotherapy on linear accelerators targets the tumour and pelvic nodes, while cisplatin given alongside makes cancer cells more sensitive to it.
High-dose-rate brachytherapy, an intracavitary irradiation, follows: an applicator is placed in the vagina and cervix and the radiation source is brought to the tumour for a short time, so the tumour gets a high dose while bowel and bladder get less. That is why it is considered a mandatory part of the course, not an option. More on brachytherapy in Germany and from Germany’s Krebsinformationsdienst.
Drug treatment and advanced disease
Drugs become the main treatment at recurrence and with distant metastases; in locally advanced disease they accompany radiotherapy. Usually this is cisplatin with paclitaxel, often plus bevacizumab, a targeted drug that blocks tumour blood-vessel growth, and immunotherapy if the cancer cells carry the PD-L1 marker. In the most advanced local stages, immunotherapy can now also be added to chemoradiation.
Marker tests and molecular profiling look for drug targets, mainly in advanced disease: PD-L1 decides whether immunotherapy is an option, and profiling occasionally finds a rare genetic change that a drug can target in any organ. A target is no promise: cervical cancer responds to drugs less well than some other gynaecological cancers.
How the estimate is built and what follows treatment
The total depends mainly on the length of chemotherapy, the complexity of radiotherapy planning and the choice of drugs. The hospital calculates it in an official estimate, the Kostenvoranschlag, with outpatient and chosen chief-physician services under the official GOÄ fee schedule. See the page on the cost of cervical cancer treatment.
Follow-up runs on a schedule, with check-ups frequent at first and rarer later. If lymph nodes were removed or irradiated, leg lymphoedema can develop: rehabilitation teaches prevention, and lymphatic drainage, exercise and compression help once it appears. Rehabilitation also treats bladder problems after surgery or radiotherapy and offers psychological support.
Frequently asked questions
Can cervical cancer be cured?
At an early stage, cervical cancer responds well to treatment. The chances depend mainly on the stage and size of the tumour, on whether cancer cells have reached the pelvic lymph nodes or those along the aorta, and on whether surgery removed the tumour completely. The treating doctor gives the individual prognosis.
How long does treatment take?
Chemoradiation including brachytherapy takes about eight weeks, so the stay in Germany should be planned for that. After surgery, further steps and their timing depend on the pathology report. Drug treatment for advanced disease continues as long as it works and is tolerated.
Can I get pregnant after treatment?
Yes, if fertility-sparing surgery such as radical trachelectomy was possible, since the body of the uterus and the ovaries remain; delivery is then usually by caesarean section. Radiotherapy can stop the ovaries working, so before chemoradiation they are sometimes moved out of the radiation field or eggs are frozen.
How AlenMed arranges treatment
AlenMed reviews records, histology and images, translates them, sends a request to a hospital with a certified gynaecological cancer centre, obtains the estimate and visa invitation, and provides an interpreter at the tumour board. Hospitals are chosen by criteria, not by rankings of “the best”: a gynaecological cancer centre certified by the German Cancer Society (DKG), a tumour board with gynaecological, radiation and medical oncologists, and radiotherapy in-house or with a regular partner. One example is Bonn University Hospital, where Prof. Alexander Mustea heads the Department of Gynaecology and Gynaecological Oncology: its cancer centre is DKG-certified, and radiotherapy is in-house. More in the overview of cancer hospitals in Germany.
The patient takes home the board’s written conclusion and a treatment and follow-up plan, translated.
This material is for reference only and is not an offer. A doctor decides on the extent of surgery and the treatment plan at an in-person consultation.
News on this topic
Tübingen researchers uncover mechanism of immune suppression during cancer cell death
Researchers at Universitätsklinikum Tübingen discovered that dying cancer cells release PGE2 to suppress immune response during ferroptosis, opening paths for combination therapy.
New single-cell lung cancer atlas LuCaS+ uses AI to predict metastasis risk
German researchers from LMU, Charité, and TU Berlin created the LuCaS+ single-cell atlas, using AI to predict lung cancer metastasis risk from archived tissue samples.
ForTra Funds Clinical Trials for Leukemia and Muscular Dystrophy
ForTra gGmbH provides four million euros to support clinical trials for acute myeloid leukemia and Duchenne muscular dystrophy in Germany.


